Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

The basic and translational science year in review: Confucius in the era of Big Data.

Pisetsky DS.

Semin Arthritis Rheum. 2020 Mar 5. pii: S0049-0172(20)30063-9. doi: 10.1016/j.semarthrit.2020.02.010. [Epub ahead of print] Review.

PMID:
32238274
2.

Of mice, men and microbes: the impact of the microbiome on immune responses.

Pisetsky DS.

Ann Rheum Dis. 2020 Feb;79(2):167-169. doi: 10.1136/annrheumdis-2020-216936. No abstract available.

PMID:
31988192
3.

The binding of SLE autoantibodies to mitochondria.

Pisetsky DS, Spencer DM, Mobarrez F, Fuzzi E, Gunnarsson I, Svenungsson E.

Clin Immunol. 2020 Mar;212:108349. doi: 10.1016/j.clim.2020.108349. Epub 2020 Jan 24.

PMID:
31982644
4.

Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.

Weinmann SC, Pisetsky DS.

Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii59-vii67. doi: 10.1093/rheumatology/kez308. Review.

5.

Evolving story of autoantibodies in systemic lupus erythematosus.

Pisetsky DS.

J Autoimmun. 2019 Dec 3:102356. doi: 10.1016/j.jaut.2019.102356. [Epub ahead of print] Review.

PMID:
31810857
6.

ANA as an entry criterion for the classification of SLE.

Pisetsky DS, Bossuyt X, Meroni PL.

Autoimmun Rev. 2019 Dec;18(12):102400. doi: 10.1016/j.autrev.2019.102400. Epub 2019 Oct 19. Review.

PMID:
31639513
7.

Role of ANA testing in the classification of patients with systemic lupus erythematosus.

Pisetsky DS, Spencer DM, Rovin B, Lipsky PE.

Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216259. doi: 10.1136/annrheumdis-2019-216259. [Epub ahead of print] No abstract available.

PMID:
31540932
8.

Response to: "How to communicate in science" by Klareskog et al.

Toes R, Pisetsky DS.

Ann Rheum Dis. 2019 Aug 13. pii: annrheumdis-2019-216045. doi: 10.1136/annrheumdis-2019-216045. [Epub ahead of print] No abstract available.

PMID:
31409590
9.

Variability in Antinuclear Antibody Testing to Assess Patient Eligibility for Clinical Trials of Novel Treatments for Systemic Lupus Erythematosus.

Pisetsky DS, Thompson DK, Wajdula J, Diehl A, Sridharan S.

Arthritis Rheumatol. 2019 Sep;71(9):1534-1538. doi: 10.1002/art.40910. Epub 2019 Aug 5.

PMID:
31385442
10.

Response to: 'Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand'' by Holmdahl.

Toes R, Pisetsky DS.

Ann Rheum Dis. 2019 Jul 3. pii: annrheumdis-2019-215870. doi: 10.1136/annrheumdis-2019-215870. [Epub ahead of print] No abstract available.

PMID:
31270108
11.

Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes.

Mobarrez F, Fuzzi E, Gunnarsson I, Larsson A, Eketjäll S, Pisetsky DS, Svenungsson E.

J Autoimmun. 2019 Aug;102:142-149. doi: 10.1016/j.jaut.2019.05.003. Epub 2019 May 16.

PMID:
31103269
12.

Unexpected link between mitochondrial DNA and T cell help in systemic lupus erythematosus.

Pisetsky DS.

Ann Rheum Dis. 2019 Jun;78(6):e59. doi: 10.1136/annrheumdis-2019-215597. No abstract available.

PMID:
31088799
13.

Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May 10. pii: annrheumdis-2019-215479. doi: 10.1136/annrheumdis-2019-215479. [Epub ahead of print] No abstract available.

PMID:
31076389
14.

Pathogenic effector functions of ACPA: Where do we stand?

Toes R, Pisetsky DS.

Ann Rheum Dis. 2019 Jun;78(6):716-721. doi: 10.1136/annrheumdis-2019-215337. Epub 2019 Apr 20. No abstract available.

15.

The central role of nucleic acids in the pathogenesis of systemic lupus erythematosus.

Pisetsky DS.

F1000Res. 2019 Apr 3;8. pii: F1000 Faculty Rev-368. doi: 10.12688/f1000research.17959.1. eCollection 2019. Review.

16.

Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2020 Mar;79(3):e33. doi: 10.1136/annrheumdis-2018-214829. Epub 2019 Jan 18. No abstract available.

PMID:
30659048
17.

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MÁ, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försönits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ 2nd, Kornek M, Kosanović MM, Kovács ÁF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstöns K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz ÁM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-'t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loghlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žėkas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK.

J Extracell Vesicles. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750. eCollection 2018.

18.

Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin B.

Ann Rheum Dis. 2020 Jan;79(1):e7. doi: 10.1136/annrheumdis-2018-214766. Epub 2018 Dec 1. No abstract available.

PMID:
30504443
19.

Response to: 'ANA testing in "real life"' by Infantino et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2020 Jan;79(1):e4. doi: 10.1136/annrheumdis-2018-214650. Epub 2018 Nov 17. No abstract available.

PMID:
30448767
20.

A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus.

Pisetsky DS, Clowse MEB, Criscione-Schreiber LG, Rogers JL.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):735-741. doi: 10.1002/acr.23794. Epub 2019 Apr 23. Review. No abstract available.

PMID:
30354033
21.

Microparticles as autoantigens in systemic lupus erythematosus.

Mobarrez F, Svenungsson E, Pisetsky DS.

Eur J Clin Invest. 2018 Dec;48(12):e13010. doi: 10.1111/eci.13010. Epub 2018 Oct 21.

PMID:
30062774
22.

Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Aug;78(8):e77. doi: 10.1136/annrheumdis-2018-213841. Epub 2018 Jun 23. No abstract available.

PMID:
29936440
23.

The SLE-key test serological signature: new insights into the course of lupus.

Putterman C, Pisetsky DS, Petri M, Caricchio R, Wu AHB, Sanz I, Oates JC, Wallace S, Sorek R, Gerwien R, Safer P, Jakobi-Brook K, Cohen IR.

Rheumatology (Oxford). 2018 Sep 1;57(9):1632-1640. doi: 10.1093/rheumatology/key149.

24.

Role of Epstein-Barr virus infection in SLE: gene-environment interactions at the molecular level.

Pisetsky DS.

Ann Rheum Dis. 2018 Sep;77(9):1249-1250. doi: 10.1136/annrheumdis-2018-213783. Epub 2018 Jun 1. No abstract available.

PMID:
29858172
25.

Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e51. doi: 10.1136/annrheumdis-2018-213582. Epub 2018 May 5. No abstract available.

PMID:
29730639
26.

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e49. doi: 10.1136/annrheumdis-2018-213558. Epub 2018 May 5. No abstract available.

PMID:
29730638
27.

Effects of immune checkpoint inhibitors on B cells: relationship to immune-related adverse events.

Pisetsky DS.

Ann Rheum Dis. 2018 Jun;77(6):795-796. doi: 10.1136/annrheumdis-2018-213561. Epub 2018 May 3. No abstract available.

PMID:
29724733
28.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e47. doi: 10.1136/annrheumdis-2018-213537. Epub 2018 Apr 28. No abstract available.

PMID:
29705742
29.

Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May;78(5):e34. doi: 10.1136/annrheumdis-2018-213399. Epub 2018 Mar 28. No abstract available.

PMID:
29592916
30.

Role of Antinuclear Antibody Determinations in Classification Criteria for Systemic Lupus Erythematosus: Comment on the Article by Leuchten et al.

Pisetsky DS, Lipsky PE.

Arthritis Care Res (Hoboken). 2019 May;71(5):696. doi: 10.1002/acr.23559. Epub 2019 Apr 10. No abstract available.

PMID:
29579355
31.

Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.

Naqvi I, Gunaratne R, McDade JE, Moreno A, Rempel RE, Rouse DC, Herrera SG, Pisetsky DS, Lee J, White RR, Sullenger BA.

Mol Ther. 2018 Apr 4;26(4):1020-1031. doi: 10.1016/j.ymthe.2018.02.018. Epub 2018 Feb 23.

32.

How the gut inflames the joints.

Pisetsky DS.

Ann Rheum Dis. 2018 May;77(5):634-635. doi: 10.1136/annrheumdis-2018-212942. Epub 2018 Mar 2. No abstract available.

PMID:
29500164
33.

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Jun;77(6):911-913. doi: 10.1136/annrheumdis-2017-212599. Epub 2018 Feb 9.

PMID:
29440000
34.

TLR3 Ligand Poly(I:C) Exerts Distinct Actions in Synovial Fibroblasts When Delivered by Extracellular Vesicles.

Frank-Bertoncelj M, Pisetsky DS, Kolling C, Michel BA, Gay RE, Jüngel A, Gay S.

Front Immunol. 2018 Jan 29;9:28. doi: 10.3389/fimmu.2018.00028. eCollection 2018.

35.

The release of microparticles and mitochondria from RAW 264.7 murine macrophage cells undergoing necroptotic cell death in vitro.

Spencer DM, Dye JR, Piantadosi CA, Pisetsky DS.

Exp Cell Res. 2018 Feb 15;363(2):151-159. doi: 10.1016/j.yexcr.2017.12.024. Epub 2017 Dec 29.

PMID:
29291399
36.

The biological functions of DNA: from the sublime to the slime.

Pisetsky DS.

Arthritis Res Ther. 2017 Dec 15;19(1):275. doi: 10.1186/s13075-017-1464-0. No abstract available.

37.

Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.

Pisetsky DS.

N C Med J. 2017 Sep-Oct;78(5):337-340. doi: 10.18043/ncm.78.5.337.

38.

Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.

Shoda LK, Battista C, Siler SQ, Pisetsky DS, Watkins PB, Howell BA.

Gene Regul Syst Bio. 2017 May 30;11:1177625017696074. doi: 10.1177/1177625017696074. eCollection 2017.

39.

Antinuclear antibody testing - misunderstood or misbegotten?

Pisetsky DS.

Nat Rev Rheumatol. 2017 Aug;13(8):495-502. doi: 10.1038/nrrheum.2017.74. Epub 2017 May 25. Review.

PMID:
28541299
40.

EULAR recommendations for disease management: guidance not guidelines.

Pisetsky DS.

Ann Rheum Dis. 2017 Jun;76(6):935-938. doi: 10.1136/annrheumdis-2016-211005. Epub 2017 May 2. No abstract available.

PMID:
28465346
41.

Mechanisms of Chromatin Remodeling and Repurposing During Extracellular Translocation.

Pisetsky DS.

Adv Protein Chem Struct Biol. 2017;106:113-137. doi: 10.1016/bs.apcsb.2016.08.003. Epub 2016 Sep 23. Review.

PMID:
28057209
42.

New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.

Pisetsky DS, Rovin BH, Lipsky PE.

Arthritis Rheumatol. 2017 Mar;69(3):487-493. doi: 10.1002/art.40008. Review. No abstract available.

43.

Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations.

Mobarrez F, Vikerfors A, Gustafsson JT, Gunnarsson I, Zickert A, Larsson A, Pisetsky DS, Wallén H, Svenungsson E.

Sci Rep. 2016 Oct 25;6:36025. doi: 10.1038/srep36025.

44.

The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.

Stearns NA, Zhou S, Petri M, Binder SR, Pisetsky DS.

PLoS One. 2016 Sep 9;11(9):e0161818. doi: 10.1371/journal.pone.0161818. eCollection 2016.

45.

The role of mitochondria in immune-mediated disease: the dangers of a split personality.

Pisetsky DS.

Arthritis Res Ther. 2016 Jul 16;18:169. doi: 10.1186/s13075-016-1063-5. No abstract available.

46.

Modified Framingham Risk Score predicted 10-y CAD better than the original score in patients with lupus.

Pisetsky DS.

Ann Intern Med. 2016 Jun 21;164(12):JC71. doi: 10.7326/ACPJC-2016-164-12-071. No abstract available.

PMID:
27323267
47.

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.

Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, Fautrel B, van Vollenhoven R.

Ann Rheum Dis. 2016 Aug;75(8):1428-37. doi: 10.1136/annrheumdis-2016-209201. Epub 2016 Jun 3. Review.

48.

The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen.

Stearns NA, Pisetsky DS.

Clin Immunol. 2016 May;166-167:38-47. doi: 10.1016/j.clim.2016.04.004. Epub 2016 Apr 12.

PMID:
27083935
49.

The Alarmin Properties of DNA and DNA-associated Nuclear Proteins.

Magna M, Pisetsky DS.

Clin Ther. 2016 May;38(5):1029-41. doi: 10.1016/j.clinthera.2016.02.029. Epub 2016 Mar 25. Review.

PMID:
27021604
50.

Anti-DNA antibodies--quintessential biomarkers of SLE.

Pisetsky DS.

Nat Rev Rheumatol. 2016 Feb;12(2):102-10. doi: 10.1038/nrrheum.2015.151. Epub 2015 Nov 19. Review.

PMID:
26581343

Supplemental Content

Loading ...
Support Center